Multiple Myeloma  >>  Decadron (dexamethasone)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Decadron (dexamethasone) / Merck (MSD)
NCT01969565: Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma

Terminated
1b
1
US
Carfilzomib, Kyprolis, Dexamethasone, Decadron
Emory University, Onyx Therapeutics, Inc.
Multiple Myeloma
10/14
10/14
NCT00091624: A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Completed
1
77
US
CC-5013
Celgene Corporation
Multiple Myeloma
09/07
09/07
NCT01680796: Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Withdrawn
1
0
US
Dovitinib, TKI258, Bortezomib, Velcade, Dexamethasone, Decadron
University of Florida, Novartis Pharmaceuticals
Multiple Myeloma
02/13
02/13
NCT01393964: Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Completed
1
35
US
Lenalidomide, Revlimid®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak® Taperpak®, Elotuzumab (BMS-901608; HuLuc63)
Bristol-Myers Squibb, AbbVie
Multiple Myeloma
03/14
07/16
NCT01660750: A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma

Completed
1
29
US
Carfilzomib, PR-171, Kyprolis, Cyclophosphamide, Cytoxan, Dexamethasone, Decadron
Criterium, Inc., Amgen
Multiple Myeloma
08/15
12/15
NCT01485835: A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Completed
1
8
US
Ganetespib, STA-9090, Bortezomib, Velcade, Dexamethasone, Decadron
Emory University, Multiple Myeloma Research Consortium, Synta Pharmaceuticals Corp.
Multiple Myeloma
09/15
09/15
NCT01549431: Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma

Completed
1
32
US
Panobinostat, LBH589, Carfilzomib, Kyprolis, Dexamethasone, Decadron
Emory University, Multiple Myeloma Research Consortium, Novartis, Onyx Therapeutics, Inc., Amgen, University of California, San Francisco, University of Chicago
Multiple Myeloma
02/16
04/17
NCT02030483: Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma

Terminated
1
9
US
Palbociclib, PD 0332991, Dexamethasone, Decadron, Lenalidomide, Revlimid
Weill Medical College of Cornell University, Celgene Corporation, Pfizer
Multiple Myeloma
07/16
07/16
NCT01440582: Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Completed
1
77
US
Panobinostat, LBH589B, Bortezomib, Velcade, LDP-341, MLN341, PS-341, Lenalidomide, CC-5013, Revlimid, Dexamethasone, Decadron, Symptom Questionnaire, Survey
M.D. Anderson Cancer Center, Novartis
Myeloma
02/19
02/19

Download Options